130 related articles for article (PubMed ID: 27288778)
21. Expanded access with intravenous hydroxypropyl-β-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis.
Hastings C; Vieira C; Liu B; Bascon C; Gao C; Wang RY; Casey A; Hrynkow S
Orphanet J Rare Dis; 2019 Oct; 14(1):228. PubMed ID: 31639011
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticles containing β-cyclodextrin potentially useful for the treatment of Niemann-Pick C.
Donida B; Raabe M; Tauffner B; de Farias MA; Machado AZ; Timm F; Kessler RG; Hammerschmidt TG; Reinhardt LS; Brito VB; Portugal RV; Bernardi A; Frozza R; Moura DJ; Giugliani R; Poletto F; Vargas CR
J Inherit Metab Dis; 2020 May; 43(3):586-601. PubMed ID: 31943253
[TBL] [Abstract][Full Text] [Related]
23. Effects of cyclodextrin in two patients with Niemann-Pick Type C disease.
Matsuo M; Togawa M; Hirabaru K; Mochinaga S; Narita A; Adachi M; Egashira M; Irie T; Ohno K
Mol Genet Metab; 2013 Jan; 108(1):76-81. PubMed ID: 23218948
[TBL] [Abstract][Full Text] [Related]
24. Application of a simple methodology to analyze Hydroxypropyl-β-Cyclodextrin in urine using HPLC-LS in early Niemann-Pick disease type C patient.
Matencio A; Alcaráz-Gómez MA; García-Carmona F; Arias B; López-Nicolás JM
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Sep; 1093-1094():47-51. PubMed ID: 29990712
[TBL] [Abstract][Full Text] [Related]
25. 2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease.
Ward S; O'Donnell P; Fernandez S; Vite CH
Pediatr Res; 2010 Jul; 68(1):52-6. PubMed ID: 20357695
[TBL] [Abstract][Full Text] [Related]
26. Increased Regenerative Capacity of the Olfactory Epithelium in Niemann-Pick Disease Type C1.
Meyer A; Wree A; Günther R; Holzmann C; Schmitt O; Rolfs A; Witt M
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28383485
[TBL] [Abstract][Full Text] [Related]
27. Low Risk Profile of Long-Term Repeated Lumbar Puncture for Intrathecal Delivery of 2-Hydroxypropyl-Beta-Cyclodextrin in Patients With Niemann-Pick Type C.
Albert OK; Friedmann K; Jaeger R; Berry-Kravis E
Pediatr Neurol; 2023 Jul; 144():99-103. PubMed ID: 37201244
[TBL] [Abstract][Full Text] [Related]
28. Neurometabolic disease: New drug slows Niemann-Pick disease.
Ridler C
Nat Rev Neurol; 2017 Oct; 13(10):576-577. PubMed ID: 28849784
[No Abstract] [Full Text] [Related]
29. HPGCD outperforms HPBCD as a potential treatment for Niemann-Pick disease type C during disease modeling with iPS cells.
Soga M; Ishitsuka Y; Hamasaki M; Yoneda K; Furuya H; Matsuo M; Ihn H; Fusaki N; Nakamura K; Nakagata N; Endo F; Irie T; Era T
Stem Cells; 2015 Apr; 33(4):1075-88. PubMed ID: 25522247
[TBL] [Abstract][Full Text] [Related]
30. Plasma signature of neurological disease in the monogenetic disorder Niemann-Pick Type C.
Alam MS; Getz M; Yi S; Kurkewich J; Safeukui I; Haldar K
J Biol Chem; 2014 Mar; 289(12):8051-66. PubMed ID: 24488491
[TBL] [Abstract][Full Text] [Related]
31. Co-treatment with probucol does not improve lung pathology in hydroxypropyl-β-cyclodextrin-treated Npc1
Erickson RP; Borbon IA
J Appl Genet; 2019 May; 60(2):175-178. PubMed ID: 30815842
[TBL] [Abstract][Full Text] [Related]
32. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease.
Camargo F; Erickson RP; Garver WS; Hossain GS; Carbone PN; Heidenreich RA; Blanchard J
Life Sci; 2001 Nov; 70(2):131-42. PubMed ID: 11787939
[TBL] [Abstract][Full Text] [Related]
33. Long-term efficacy of intrathecal cyclodextrin in patients with Niemann-Pick disease type C.
Matsuo M; Sakakibara T; Sakiyama Y; So T; Kosuga M; Kakiuchi T; Ichinose F; Nakamura T; Ishitsuka Y; Irie T
Brain Dev; 2024 May; 46(5):207-212. PubMed ID: 38448301
[TBL] [Abstract][Full Text] [Related]
34. Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model.
Alam MS; Getz M; Haldar K
Sci Transl Med; 2016 Feb; 8(326):326ra23. PubMed ID: 26888431
[TBL] [Abstract][Full Text] [Related]
35. A pilot study of direct delivery of hydroxypropyl-beta-cyclodextrin to the lung by the nasal route in a mouse model of Niemann-Pick C1 disease: motor performance is unaltered and lung disease is worsened.
Erickson RP; Deutsch G; Patil R
J Appl Genet; 2018 May; 59(2):187-191. PubMed ID: 29411332
[TBL] [Abstract][Full Text] [Related]
36. Impact of miglustat on evolution of atypical presentation of late-infantile-onset Niemann-Pick disease type C with early cognitive impairment, behavioral dysfunction, epilepsy, ophthalmoplegia, and cerebellar involvement: a case report.
Cuisset JM; Sukno S; Trauffler A; Latour P; Dobbelaere D; Michaud L; Vallée L
J Med Case Rep; 2016 Sep; 10(1):241. PubMed ID: 27599728
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in the treatment of Niemann pick disease type C: A mini-review.
Matencio A; Navarro-Orcajada S; González-Ramón A; García-Carmona F; López-Nicolás JM
Int J Pharm; 2020 Jun; 584():119440. PubMed ID: 32428546
[TBL] [Abstract][Full Text] [Related]
38. Cyclodextrin-Based Macromolecular Systems as Cholesterol-Mopping Therapeutic Agents in Niemann-Pick Disease Type C.
Puglisi A; Yagci Y
Macromol Rapid Commun; 2019 Jan; 40(1):e1800557. PubMed ID: 30216584
[TBL] [Abstract][Full Text] [Related]
39. Mutant human APP exacerbates pathology in a mouse model of NPC and its reversal by a β-cyclodextrin.
Maulik M; Ghoshal B; Kim J; Wang Y; Yang J; Westaway D; Kar S
Hum Mol Genet; 2012 Nov; 21(22):4857-75. PubMed ID: 22869680
[TBL] [Abstract][Full Text] [Related]
40. Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder.
Kulkarni A; Caporali P; Dolas A; Johny S; Goyal S; Dragotto J; Macone A; Jayaraman R; Fiorenza MT
Sci Rep; 2018 Jun; 8(1):9547. PubMed ID: 29934581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
